Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India
about
Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?Poor outcomes in a cohort of HIV-infected adolescents undergoing treatment for multidrug-resistant tuberculosis in Mumbai, IndiaDoing no harm? Adverse events in a nation-wide cohort of patients with multidrug-resistant tuberculosis in NigeriaMycobacterium tuberculosis and Human Immunodeficiency Virus Type 1 Cooperatively Modulate Macrophage Apoptosis via Toll Like Receptor 2 and Calcium HomeostasisPatient and Provider Reported Reasons for Lost to Follow Up in MDRTB Treatment: A Qualitative Study from a Drug Resistant TB Centre in IndiaLinezolid-Associated Optic Neuropathy in Drug-Resistant Tuberculosis Patients in Mumbai, IndiaAdverse Events Associated with Treatment of Multidrug-Resistant Tuberculosis in China: An Ambispective Cohort Study.Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosisSecond-line failure and first experience with third-line antiretroviral therapy in Mumbai, India.Patch-testing for the management of hypersensitivity reactions to second-line anti-tuberculosis drugs: a case reportHIV, multidrug-resistant TB and depressive symptoms: when three conditions collideTreatment outcomes for patients with multidrug-resistant tuberculosis in post-earthquake Port-au-Prince, Haiti.Occurrence and clinical management of moderate-to-severe adverse events during drug-resistant tuberculosis treatment: a retrospective cohort studyManagement of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review.Ocular inflammatory disease and ocular tuberculosis in a cohort of patients co-infected with HIV and multidrug-resistant tuberculosis in Mumbai, India: a cross-sectional studyA pilot study of an mHealth application for healthcare workers: poor uptake despite high reported acceptability at a rural South African community-based MDR-TB treatment program.High rate of hypothyroidism in multidrug-resistant tuberculosis patients co-infected with HIV in Mumbai, IndiaInfection control in households of drug-resistant tuberculosis patients co-infected with HIV in Mumbai, India.The need to accelerate access to new drugs for multidrug-resistant tuberculosis.Time to ART Initiation among Patients Treated for Rifampicin-Resistant Tuberculosis in Khayelitsha, South Africa: Impact on Mortality and Treatment Success.Management of multi- and extensively drug-resistant tuberculosis in Ukraine: how well are we doing?Adverse Drug Reaction Profile in Patients on Anti-tubercular Treatment Alone and in Combination with Highly Active Antiretroviral Therapy.Evaluation of community-based treatment for drug-resistant tuberculosis in BangladeshAdverse events in an integrated home-based treatment program for MDR-TB and HIV in KwaZulu-Natal, South Africa.Thyroid function in multidrug-resistant tuberculosis patients with or without human immunodeficiency virus (HIV) infection before commencement of MDR-TB drug regimen.Clinical profile and treatment outcomes of drug-resistant tuberculosis before directly observed treatment strategy plus: Lessons for the program.Treatment Outcomes for Adolescents With Multidrug-Resistant Tuberculosis in Lima, Peru.Predictors of cure among HIV co-infected multidrug-resistant TB patients at Sizwe Tropical Disease Hospital Johannesburg, South Africa.A systematic review and meta-analysis of the efficacy and safety of N-acetylcysteine in preventing aminoglycoside-induced ototoxicity: implications for the treatment of multidrug-resistant TB.Management of drug resistantTB in patients with HIV co-infection.Dilemma of managing asymptomatic children referred with 'culture-confirmed' drug-resistant tuberculosisAdverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis.Programmatic treatment outcomes in HIV-infected and uninfected drug-resistant TB patients in Khayelitsha, South Africa.Adverse events during treatment of drug-resistant tuberculosis: a comparison between patients with or without human immunodeficiency virus co-infection.'I cry every day': experiences of patients co-infected with HIV and multidrug-resistant tuberculosis.Increased risk of aminoglycoside-induced hearing loss in MDR-TB patients with HIV coinfection.Effect of lidocaine on kanamycin injection-site pain in patients with multidrug-resistant tuberculosis"Life continues": Patient, health care and community care workers perspectives on self-administered treatment for rifampicin-resistant tuberculosis in Khayelitsha, South Africa
P2860
Q26771997-A78D0535-4004-4451-A008-E69B4913F468Q28534754-F053A513-2254-4DFD-8130-448CB03F840EQ28544462-AE3117D5-5858-4B77-8215-B88B7C2D3204Q28546086-D707724B-21E9-44EF-802E-E89CF1850D13Q28547430-111DEC82-1659-4B33-B93B-27545B365B76Q28553960-1ACB360D-858D-4FFC-841F-9F9CCD7AA660Q33728573-0AAE7EFD-9AAB-488E-BAF3-330CF4CACEE5Q33926262-A4E27F5B-085A-4F02-BB63-225E0BAF994DQ33991040-58E64832-8AA0-4DBD-B48B-557150F87E5BQ34076558-657A119E-6BC7-4DB9-86CC-84B2C70BE3B0Q34168161-77A267FA-5C52-4999-8B5A-2E488DE408BFQ34281547-56B4B6CC-5E88-4C09-BE2A-B20645CDE611Q34447192-71AFC565-CB00-4960-93C7-55FB7D72271FQ34455442-786583DA-6C30-4ADD-93DB-B0C3CCA65234Q34728730-6338B24A-8B78-49A3-A346-47658F53FA02Q34749709-7CD86755-CDBF-4693-B2B2-55BD7AC5B325Q35032535-FB462307-056D-43A4-BA18-1F1048F1B329Q35775597-750793B5-44A2-4981-8619-A2ED39DB2B38Q35815071-EC493BC0-6EED-4F38-A2AF-DCA165ECED94Q35837236-5C3AA57D-0B4D-4A9F-813C-57394DA47889Q35990636-5F31D1FB-972E-4DCC-9A05-ED8A7F3BF43AQ36221959-CF038182-AB09-4062-A62C-31E81DBB6A0BQ36479814-88DC6C99-BE38-41AD-B588-B2F8D56A5C3BQ36809098-2EB31063-D7C6-416C-B2AB-16070AF3F1A0Q37196818-07A6E8CE-C487-4D8C-B13D-6D4DB7C60EF7Q37345726-EA9ED9E3-A10D-4ED2-B156-1FCA26D2B27FQ37375069-0F4CEF6A-E07E-4F3C-A1DE-9A6F8F521C62Q38383242-9A8F5529-3BAC-4283-8AC9-D8088490D11FQ38582633-98EE01D3-8788-487F-A4E1-07467264705AQ38610637-9F2FE751-5247-49E5-9DEE-A1704FEC5018Q38797948-084B2C50-FD7A-4F85-9CBB-F41091D2696BQ39248451-C049C8AA-933F-4832-B0AF-2B6F2630AFEEQ40934368-A814BA5B-9EA9-4077-AFFC-1BBD2D481AD0Q42278836-F463B2C9-C5EF-4BDF-92AE-72CE2DF64A82Q46153182-0C9D9B24-28AF-4755-BD40-4C2EC5F010D5Q55407610-56ACF793-EEA6-4180-8EE9-F256EE9BBBFCQ56949160-C73E160C-E864-4CDD-8584-B434568E32A3Q58741213-990EF3B2-508A-415E-A784-6C7E131E3724
P2860
Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Adverse events among HIV/MDR-T ...... -TB treatment in Mumbai, India
@ast
Adverse events among HIV/MDR-T ...... -TB treatment in Mumbai, India
@en
Adverse events among HIV/MDR-T ...... -TB treatment in Mumbai, India
@nl
type
label
Adverse events among HIV/MDR-T ...... -TB treatment in Mumbai, India
@ast
Adverse events among HIV/MDR-T ...... -TB treatment in Mumbai, India
@en
Adverse events among HIV/MDR-T ...... -TB treatment in Mumbai, India
@nl
prefLabel
Adverse events among HIV/MDR-T ...... -TB treatment in Mumbai, India
@ast
Adverse events among HIV/MDR-T ...... -TB treatment in Mumbai, India
@en
Adverse events among HIV/MDR-T ...... -TB treatment in Mumbai, India
@nl
P2093
P2860
P50
P921
P3181
P1433
P1476
Adverse events among HIV/MDR-T ...... -TB treatment in Mumbai, India
@en
P2093
Bhanumati Varghese
Esdras Da Silva
Homa Mansoor
Joanna Ladomirska
Peter Saranchuk
Roma Paryani
Samsuddin Khan
Zarir Udwadia
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0040781
P407
P577
2012-01-01T00:00:00Z